Study on encapsulation and properties vitamin A acetate/cyclodextrin

doi:10.11949/0438-1157.20240291

Abstract

Abstract:

The inclusion complexes of VAA with β-cyclodextrin (β-CD) and its derivatives hydroxypropyl β- cyclodextrin (HP-β-CD) and sulfobutyl ether β-cyclodextrin (SBE-β-CD) were prepared by freeze-drying method, and the inclusion complexes were characterized by Fourier infrared spectroscopy (FT-IR), nuclear magnetic resonance hydrogen spectroscopy (¹H NMR), and scanning electron microscope (SEM), and phase solubility, thermal stability, solubility and molecular binding mode were analyzed. The results of the phase solubility experiments showed that all the three cyclodextrins formed an inclusion ratio of 1∶1 with VAA, among which HP-β-CD had the highest stability constant and was more effective than the other two cyclodextrins in the inclusion of VAA. The experimental results of thermal stability and solubility change tests showed that the thermal stability and water solubility of the three inclusion compounds were substantially improved compared with free VAA, with VAA/HP-β-CD being the best, with the heat loss rate decreasing from 52.6% to 5.2%; and the water solubility increasing from 1.9×10^-4 to 100 g/100 g. The results of the molecular docking showed that HP-β-CD enlarged the β-CD cavity length so that VAA was completely encapsulated and formed intermolecular hydrogen bonding with VAA, and the inclusion complex formed with VAA had minimal binding energy. The above results indicate that HP-β-CD is an excellent encapsulation carrier for VAA and can effectively improve the application performance of VAA.

Key words: vitamin A acetate, cyclodextrin, stability, solubility, molecular simulation

摘要：

通过冷冻干燥法制备了维生素A醋酸酯（VAA）和β环糊精（β-CD）及其衍生物羟丙基β环糊精（HP-β- CD）、磺丁基醚β环糊精（SBE-β-CD）的包合物，采用傅里叶红外光谱（FT-IR）、核磁共振氢谱（¹H NMR）和扫描电子显微镜（SEM）对包合物进行了表征，并对包合物的相溶解度、热稳定性、溶解度和分子结合模式进行了分析。相溶解度实验结果表明三种环糊精均与VAA形成包合比为1∶1的包合物，其中HP-β-CD的稳定常数最高，对VAA的包合效果要优于另外两种环糊精。热稳定性和溶解度变化测试实验结果表明，与游离VAA相比，三种包合物的热稳定性和水溶性均有大幅提高，其中VAA/HP-β-CD的效果最好，热损失率由52.6%下降至5.2%；水溶解度由1.9×10^-4增至100 g/100 g。分子对接结果表明，HP-β-CD扩大了β-CD空腔长度，使VAA被完全包裹，并和VAA形成了分子间氢键，与VAA形成的包合物具有最小结合能。上述研究结果表明HP-β-CD是VAA的优良包合载体，能有效提高VAA的应用性能。

关键词: 维生素A醋酸酯, 环糊精, 稳定性, 溶解性, 分子模拟

CLC Number:

O 648.25

Xinyue WANG, Xiaohu XU, Haiyang ZHANG, Chunhua YIN. Study on encapsulation and properties vitamin A acetate/cyclodextrin[J]. CIESC Journal, 2024, 75(S1): 321-328.

王新月, 徐小虎, 张海洋, 尹春华. 维生素A醋酸酯/环糊精包合及性质研究[J]. 化工学报, 2024, 75(S1): 321-328.

Figures/Tables 9

References 30

1	Gianeti M D, Gaspar L R, de Camargo F B, et al. Benefits of combinations of Vitamin A, C and E derivatives in the stability of cosmetic formulations[J]. Molecules, 2012, 17(2): 2219-2230.
2	Sachdeva B, Kaushik R, Arora S, et al. Effect of processing conditions on the stability of native Vitamin A and fortified retinol acetate in milk[J]. International Journal for Vitamin and Nutrition Research, 2021, 91(1/2): 133-142.
3	Zhou J J, Jia J L, He J L, et al. Cyclodextrin inclusion complexes and their application in food safety analysis: recent developments and future prospects[J]. Foods, 2022, 11(23): 3871.
4	Nowak J K, Sobkowiak P, Drzymała-Czyż S, et al. Fat-soluble vitamin supplementation using liposomes, cyclodextrins, or medium-chain triglycerides in cystic fibrosis: a randomized controlled trial[J]. Nutrients, 2021, 13(12): 4554.
5	de Melo C G, da Costa L A G, Rabello M M, et al. Enhanced solubility of albendazole in cyclodextrin inclusion complex: a molecular modeling approach and physicochemical evaluation[J]. Current Drug Delivery, 2022, 19(1): 86-92.
6	Aman A, Ali S, Mahalapbutr P, et al. Enhancing solubility and stability of sorafenib through cyclodextrin-based inclusion complexation: in silico and in vitro studies[J]. RSC Advances, 2023, 13(39): 27244-27254.
7	Li Q, Pu H Y, Tang P X, et al. Propyl gallate/cyclodextrin supramolecular complexes with enhanced solubility and radical scavenging capacity[J]. Food Chemistry, 2018, 245: 1062-1069.
8	Biernacka M, Ilyich T, Zavodnik I, et al. Studies of the formation and stability of ezetimibe-cyclodextrin inclusion complexes[J]. International Journal of Molecular Sciences, 2021, 23(1): 455.
9	Lin H S, Leong W W Y, Yang J A, et al. Biopharmaceutics of 13-cis-retinoic acid (isotretinoin) formulated with modified beta-cyclodextrins[J]. International Journal of Pharmaceutics, 2007, 341(1/2): 238-245.
10	Yap K L, Liu X, Thenmozhiyal J C, et al. Characterization of the 13-cis-retinoic acid/cyclodextrin inclusion complexes by phase solubility, photostability, physicochemical and computational analysis[J]. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences, 2005, 25(1): 49-56.
11	Higuchi T A, Connors K A. Phase-Solubility Techniques[M]. New York: Interscience, 1965.
12	Fateminasab F, Bordbar A K, Shityakov S, et al. Diadzein complexation with unmodified cyclodextrins: a detailed experimental and theoretical study[J]. Journal of Molecular Liquids, 2018, 271: 80-95.
13	吴海波, 方岩雄, 纪红兵. 助溶剂促进的β-环糊精与肉桂醛的包结性能[J]. 化工学报, 2011, 62(S1): 168-173.
	Wu H B, Fang Y X, Ji H B. Inclusion properties of β-cyclodextrin with cinnamaldehyde promoted by cosolvent[J]. CIESC Journal, 2011, 62(S1): 168-173.
14	姚培培, 樊金玲, 李德锋, 等. 光甘草定/环糊精固体包合物的制备和性质[J]. 食品科学, 2022, 43(16): 9-18.
	Yao P P, Fan J L, Li D F, et al. Preparation and characterization of glabridin/cyclodextrin solid inclusion complex[J]. Food Science, 2022, 43(16): 9-18.
15	Ntountaniotis D, Leonis G, Christodoulou E, et al. Applications of NMR in drug: cyclodextrin complexes[J]. Methods in Molecular Biology, 2021, 2207: 313-325.
16	Szabó Z I, Ludmerczki R, Fiser B, et al. Chiral separation of rasagiline using s u l f o b u t y l e t h e r - β - c y c l o d e x t r i n : capillary electrophoresis, NMR and molecular modeling study[J]. Electrophoresis, 2019, 40(15): 1897-1903.
17	Betlejewska-Kielak K, Bednarek E, Budzianowski A, et al. Comprehensive characterisation of the ketoprofen-β-cyclodextrin inclusion complex using X-ray techniques and NMR spectroscopy[J]. Molecules, 2021, 26(13): 4089.
18	高珊, 徐磊, 王心, 等. 薏米麸皮多酚-β-环糊精包合物特性研究[J]. 中国食品学报, 2022, 22(6): 117-124.
	Gao S, Xu L, Wang X, et al. Stuides on characterization of inclusion complex of adlay bran polyphenols with β-cyclodextrin[J]. Journal of Chinese Institute of Food Science and Technology, 2022, 22(6): 117-124.
19	Giri B R, Lee J, Lim D Y, et al. Docetaxel/dimethyl-β- cyclodextrin inclusion complexes: preparation, in vitro evaluation and physicochemical characterization[J]. Drug Development and Industrial Pharmacy, 2021, 47(2): 319-328.
20	Xu X H, Peng S Y, Bao G K, et al. β-Cyclodextrin inclusion complexes with Vitamin A and its esters: a comparative experimental and molecular modeling study[J]. Journal of Molecular Structure, 2021, 1223: 129001.
21	Celebioglu A, Uyar T. Design of polymer-free Vitamin-A acetate/cyclodextrin nanofibrous webs: antioxidant and fast-dissolving properties[J]. Food & Function, 2020, 11(9): 7626-7637.
22	Carlotti M E, Rossatto V, Gallarate M. Vitamin A and Vitamin A palmitate stability over time and under UVA and UVB radiation[J]. International Journal of Pharmaceutics, 2002, 240(1/2): 85-94.
23	Wang F, Yu W B, Popesceu C, et al. Cholecalciferol complexation with hydroxypropyl-β-cyclodextrin (HPBCD) and its molecular dynamics simulation[J]. Pharmaceutical Development and Technology, 2022, 27(4): 389-398.
24	Zhu G Y, Xiao Z B, Zhu G X. Fabrication and characterization of ethyl acetate-hydroxypropyl-β-cyclodextrin inclusion complex[J]. Journal of Food Science, 2021, 86(8): 3589-3597.
25	Vilanova N, Solans C. Vitamin A Palmitate-β-cyclodextrin inclusion complexes: characterization, protection and emulsification properties[J]. Food Chemistry, 2015, 175: 529-535.
26	Sid D, Baitiche M, Elbahri Z, et al. Solubility enhancement of mefenamic acid by inclusion complex with β-cyclodextrin: in silico modelling, formulation, characterisation, and invitro studies[J]. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36(1): 605-617.
27	Patil S M, Barji D S, Chavan T, et al. Solubility enhancement and inhalation delivery of cyclodextrin-based inclusion complex of delamanid for pulmonary tuberculosis treatment[J]. AAPS PharmSciTech, 2023, 24(1): 49.
28	Loh G O K, Tan Y T F, Peh K K. Enhancement of norfloxacin solubility via inclusion complexation with β-cyclodextrin and its derivative hydroxypropyl-β-cyclodextrin[J]. Asian Journal of Pharmaceutical Sciences, 2016, 11(4): 536-546.
29	Zhong Y Y, Li W H, Ran L D, et al. Inclusion complexes of tea polyphenols with H P - β - c y c l o d e x t r i n : preparation, characterization, molecular docking, and antioxidant activity[J]. Journal of Food Science, 2020, 85(4): 1105-1113.
30	Chang C K, Song M, Ma M X, et al. Preparation, characterization and molecular dynamics simulation of rutin-cyclodextrin inclusion complexes[J]. Molecules, 2023, 28(3): 955.

样品化学位移	H-1	H-3	H-6	H-5	H-2	H-4
δ(free β-CD)	5.009	3.910	3.821	3.806	3.602	3.527
δ(VAA/β-CD)	4.997	3.885	3.818	3.785	3.593	3.524
Δδ (VAA/β-CD)	-0.012	-0.025	-0.003	-0.021	-0.009	-0.003
δ(free HP-β-CD)	4.989	3.853	3.784	3.761	3.638	3.520
δ(VAA/ HP-β-CD)	4.981	3.828	3.782	3.734	3.636	3.511
Δδ(VAA/ HP-β-CD)	-0.008	-0.025	-0.002	-0.027	-0.002	-0.009
δ(free SBE-β-CD)	4.978	3.880	3.792	3.768	3.579	3.497
δ(VAA/SBE-β-CD)	4.966	3.844	3.783	3.735	3.565	3.498
Δδ (VAA/SBE-β-CD)	-0.012	-0.036	-0.009	-0.033	-0.014	0.001

样品化学位移	H-1	H-3	H-6	H-5	H-2	H-4
δ(free β-CD)	5.009	3.910	3.821	3.806	3.602	3.527
δ(VAA/β-CD)	4.997	3.885	3.818	3.785	3.593	3.524
Δδ (VAA/β-CD)	-0.012	-0.025	-0.003	-0.021	-0.009	-0.003
δ(free HP-β-CD)	4.989	3.853	3.784	3.761	3.638	3.520
δ(VAA/ HP-β-CD)	4.981	3.828	3.782	3.734	3.636	3.511
Δδ(VAA/ HP-β-CD)	-0.008	-0.025	-0.002	-0.027	-0.002	-0.009
δ(free SBE-β-CD)	4.978	3.880	3.792	3.768	3.579	3.497
δ(VAA/SBE-β-CD)	4.966	3.844	3.783	3.735	3.565	3.498
Δδ (VAA/SBE-β-CD)	-0.012	-0.036	-0.009	-0.033	-0.014	0.001

样品	T/K	S₀/mol	Slope×10^-3	K×10³/(1/mol)	ΔG/(kJ/mol)	ΔH/(kJ/mol)	ΔS/(kJ/mol)
	283	(1.264±0.018)×10^-6	3.333±0.026	2.646±0.017	-18.543±0.016	-82.520±0.384	-0.226±0.001
β-CD	285	(0.958±0.027)×10^-6	2.08±0.004	2.176±0.057	-18.210±0.063	-82.520±0.384	-0.226±0.002
	288	(1.409±0.015)×10^-6	2.037±0.008	1.448±0.009	-17.427±0.015	-82.520±0.384	-0.226±0.001
	283	(1.175±0.014)×10^-7	5.049±0.026	43.185±0.29	-25.113±0.016	-252.085±0.593	-0.802±0.002
HP-β-CD	285	(2.191±0.053)×10^-7	5.281±0.025	24.242±0.47	-23.922±0.046	-252.085±0.593	-0.801±0.002
	288	(7.731±0.128)×10^-7	5.279±0.065	6.864±0.029	-21.153±0.010	-252.085±0.593	-0.802±0.002
	283	(1.368±0.001) ×10^-6	5.896±0.007	4.337±0.007	-19.705±0.004	-100.383±0.270	-0.285±0.001
SBE-β-CD	285	(2.133±0.003)×10^-6	5.427±0.017	2.646±0.017	-18.594±0.004	-100.383±0.270	-0.287±0.001
	288	(2.651±0.011)×10^-6	5.304±0.002	2.646±0.017	-18.214±0.009	-100.383±0.270	-0.285±0.001

样品	T/K	S₀/mol	Slope×10^-3	K×10³/(1/mol)	ΔG/(kJ/mol)	ΔH/(kJ/mol)	ΔS/(kJ/mol)
	283	(1.264±0.018)×10^-6	3.333±0.026	2.646±0.017	-18.543±0.016	-82.520±0.384	-0.226±0.001
β-CD	285	(0.958±0.027)×10^-6	2.08±0.004	2.176±0.057	-18.210±0.063	-82.520±0.384	-0.226±0.002
	288	(1.409±0.015)×10^-6	2.037±0.008	1.448±0.009	-17.427±0.015	-82.520±0.384	-0.226±0.001
	283	(1.175±0.014)×10^-7	5.049±0.026	43.185±0.29	-25.113±0.016	-252.085±0.593	-0.802±0.002
HP-β-CD	285	(2.191±0.053)×10^-7	5.281±0.025	24.242±0.47	-23.922±0.046	-252.085±0.593	-0.801±0.002
	288	(7.731±0.128)×10^-7	5.279±0.065	6.864±0.029	-21.153±0.010	-252.085±0.593	-0.802±0.002
	283	(1.368±0.001) ×10^-6	5.896±0.007	4.337±0.007	-19.705±0.004	-100.383±0.270	-0.285±0.001
SBE-β-CD	285	(2.133±0.003)×10^-6	5.427±0.017	2.646±0.017	-18.594±0.004	-100.383±0.270	-0.287±0.001
	288	(2.651±0.011)×10^-6	5.304±0.002	2.646±0.017	-18.214±0.009	-100.383±0.270	-0.285±0.001

样品	溶解度/(g/100 g)
Free VAA	1.9×10^-4
VAA/β-CD	0.85±0.05
VAA/HP-β-CD	100±0.04
VAA/SBE-β-CD	1.48±0.05